Off-label drug use in the treatment of polycystic ovary syndrome

Fertility and Sterility
Wendy VitekKathleen M Hoeger

Abstract

Polycystic ovary syndrome (PCOS) is a complex lifelong disorder with an etiology and pathophysiology that is not yet entirely understood. Women with PCOS have clinical presentations that may vary from adolescence to menopause, including menstrual irregularity/anovulation and symptoms of hyperandrogenism, such as acne and hirsutism. Over a lifetime, treatment needs and requirements can change. Unfortunately, there are no Food and Drug Administration-approved medications that are approved solely for the purpose of PCOS, but the symptoms and presentation of PCOS are often amenable to several approved agents, such as oral contraceptives for the indication of acne and clomiphene citrate for the indication of induction of ovulation. However, to meet the needs of women with PCOS, off-label use of medications has flourished. This review explores the data for those agents that do not carry an indication for PCOS but have been used for treating the signs and symptoms of PCOS.

References

Jan 1, 1988·The Journal of Clinical Endocrinology and Metabolism·E L HelferL I Rose
Oct 20, 1999·European Journal of Endocrinology·L FalsettiG Bugari
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Dec 23, 2003·Human Reproduction·UNKNOWN Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group
Mar 31, 2005·The Journal of Clinical Endocrinology and Metabolism·Richard S LegroAndrea Dunaif
Jun 27, 2006·Fertility and Sterility·Lourdes Ibáñez, Francis de Zegher
Jan 31, 2007·Human Reproduction·Michael F CostelloPeter Sjoblom
Feb 9, 2007·The New England Journal of Medicine·Richard S LegroUNKNOWN Cooperative Multicenter Reproductive Medicine Network
May 8, 2008·The Journal of Clinical Endocrinology and Metabolism·Karen Elkind-HirschRajat Bhushan
May 31, 2008·European Journal of Endocrinology·Jana VrbikovaGiovanni Pacini
Jun 13, 2009·Physiology & Behavior·Siew S LimManny Noakes
Nov 6, 2009·Obstetrics and Gynecology·UNKNOWN ACOG Committee on Practice Bulletins--Gynecology
Jul 1, 2010·Dermatology : International Journal for Clinical and Investigative Dermatology·M LapidothUNKNOWN expert working group
Sep 10, 2010·The Journal of Clinical Endocrinology and Metabolism·Anna SokalskaAntoni J Duleba
Feb 23, 2011·International Journal of Women's Health·Ahmed Badawy, Abubaker Elnashar
Sep 9, 2011·International Journal of Pediatric Endocrinology·David H GellerUNKNOWN of the Drug and Therapeutics Committee of the Pediatric Endocrine Society
Sep 21, 2011·The Medical Journal of Australia·Helena J TeedeUNKNOWN Guideline Development Groups
Sep 26, 2012·Acta Obstetricia Et Gynecologica Scandinavica·Eszter VankySven M Carlsen
Oct 18, 2012·Seminars in Reproductive Medicine·Richard S Legro
Jan 19, 2013·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Roberto ParadisiStefano Venturoli
Oct 24, 2013·The Journal of Clinical Endocrinology and Metabolism·Richard S LegroUNKNOWN Endocrine Society
Jan 1, 2014·Clinical Epidemiology·Susan M Sirmans, Kristen A Pate
Jun 6, 2014·Expert Review of Clinical Pharmacology·Vittorio Unfer, Giuseppina Porcaro
Sep 16, 2014·Frontiers in Endocrinology·Christina B Rasmussen, Svend Lindenberg

❮ Previous
Next ❯

Citations

Dec 21, 2018·The Cochrane Database of Systematic Reviews·Marian G ShowellCindy Farquhar
Jan 1, 2021·Expert Review of Endocrinology & Metabolism·Georgios PapadakisMelpomeni Peppa
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sarah L MuellerSally-Ann Poulsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.